Ladenburg Thalmann Starts Bellicum Pharmaceuticals (BLCM) at Buy
- Wall Street flat as telecom gains fail to counter oil drop
- Equinix (EQIX) Announces $3.6B Acquisition of Data Center Portfolio from Verzion (VZ)
- Deal Progress Said to Slow as Johnson & Johnson (JNJ) Puts Actelion (ALIOY) Under Microscope - Source
- Trump Wants to Cancel New Air Force One Order with Boeing (BA)
- Roper Industries (ROP) to acquire Deltek in $2.8B Deal
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Ladenburg Thalmann initiated coverage on Bellicum Pharmaceuticals (NASDAQ: BLCM) with a Buy rating and a price target of $31.00.
Shares of Bellicum Pharmaceuticals closed at $19.16 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bellicum Pharma (BLCM) Offers BPX-501 Update at ASH 2016
- KLR Group Starts Resolute Energy (REN) at Buy
- Benchmark Starts SPS Commerce (SPSC) at Buy
Create E-mail Alert Related CategoriesNew Coverage
Related EntitiesLadenburg Thalmann Financial Services
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!